325
Participants
Start Date
April 12, 2017
Primary Completion Date
February 15, 2018
Study Completion Date
March 8, 2018
Oritavancin
This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.
New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn
Erie County Medical Center, Buffalo
Allegheny General Hospital, Pittsburgh
University of Pittsburgh Medical Center, Pittsburgh
TruCare Internal Medicine and Infectious Diseases, DuBois
WellStar Health System - Kennestone, Marietta
Florida Infectious Disease Care, Fort Myers
Infectious Diseases Associates of North Central Florida, LLC, Ocala
Birmingham Infectious Disease and Infusion, Birmingham
St. Vincent Hospital and Health Care Center, Inc., Indianapolis
Methodist Jennie Edmundson Hospital, Council Bluffs
Trinity Health Medical Group, Minot
IDC Clinical Research, LLC, Wichita
Infectious Diseases Consultants of OKC, Oklahoma City
Houston Center For Infectious Diseases, The Woodlands
Infectious Disease and Pulmonary, Victoria
Center for Infectious Diseases & Travel Medicine, El Paso
Snake River Research, PLLC, Idaho Falls
Foot & Ankle Institute, St. George
Clinical Infectious Disease Specialists, Las Vegas
Santa Barbara Cottage Hospital, Santa Barbara
Lead Sponsor
Melinta Therapeutics, Inc.
INDUSTRY